Big Pharma's Fears Unfounded as RFK's Vaccine Stance Deemed Moderate
Robert F. Kennedy Jr.'s nomination for Health and Human Services (HHS) secretary has raised concerns among pharmaceutical companies. However, Pfizer CEO Albert Bourla contends that Kennedy's views are not as extreme as perceived.
In closed-door meetings, Kennedy has reportedly moderated his stance on vaccines, according to Bourla. This aligns with assessments from others who have met with him.
Kennedy's nomination has nonetheless faced opposition from medical and scientific organizations due to his past actions against the pharmaceutical industry. Despite these concerns, Bourla and others have expressed support for his appointment.
Trump's avoidance of health crises and the need for a more moderate tone appear to have influenced Kennedy's stance on vaccines. During confirmation hearings, he claimed to support childhood vaccine schedules but declined to acknowledge their safety and effectiveness.
Bourla's existing relationship with Trump and his upcoming role as chair of PhRMA will provide Pfizer with significant leverage within the industry.
Bourla predicts a positive trajectory for the industry under the Trump administration, citing its support for cancer research and opposition to Biden-era policies.
The potential impact of Medicare drug pricing negotiations on Pfizer's revenue remains uncertain, but the expiring patents on Ibrance and Xtandi should mitigate any significant losses.